Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, the Company issued a press release announcing certain preliminary financial results and providing certain other information for the quarter and year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 (the "Press Release").

The financial data contained therein are unaudited, preliminary, based upon the Company's good faith estimates and subject to completion of the Company's financial closing procedures. While the Company expects that its final financial results for the quarter and year ended December 31, 2022, following the completion of its financial closing procedures, will generally be consistent with the information provided in the Press Release, the Company's actual results may differ materially from these estimates as a result of the completion of its financial closing procedures for the quarter and year ended December 31, 2022, as well as final adjustments and other developments that may arise between now and the time that its financial results for the quarter and year ended December 31, 2022 are finalized.

The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits
Exhibit No.        Description

99.1                 Press Release of NovoCure Limited, dated January 9, 2023
104                Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses